Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations
AIDS2024Vol. 38(6), pp. 847–851
Citations Over TimeTop 19% of 2024 papers
Dario Cattaneo, Simone Pagano, Martina Laura Colombo, Andrea Giacomelli, Andrea Gori, Cristina Gervasoni
Abstract
Dolutegravir trough concentrations are differently affected by individual antiretroviral drugs, with some drug combinations (i.e. dolutegravir/darunavir/cobicistat, or dolutegravir/rilpivirine) providing significantly higher than expected dolutegravir exposure. Such combinations might be advantageous when there are concerns about dolutegravir plasma exposure or resistance.
Related Papers
- → Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS(2016)15 cited
- → Darunavir/cobicistat once daily for the treatment of HIV(2015)17 cited
- → Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers(2007)28 cited
- → Darunavir/cobicistat fixed-dose single tablet (Rezolsta™): a guide to its use in HIV-1 infection in adults in the EU(2015)1 cited
- [Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection].(2014)